BSF Enterprise (BSFA) Competitors

BSF Enterprise logo
GBX 0.90 -0.17 (-15.49%)
As of 12:37 PM Eastern

BSFA vs. RGT, CEL, IDP, HALO, and OPTI

Should you buy BSF Enterprise stock or one of its competitors? BSF Enterprise's main competitors and comparable companies include Argent BioPharma (RGT), Celadon Pharmaceuticals (CEL), InnovaDerma (IDP), HaloSource (HALO), and OptiBiotix Health (OPTI). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does BSF Enterprise compare to Argent BioPharma?

Argent BioPharma (LON:RGT) and BSF Enterprise (LON:BSFA) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, valuation, risk, dividends, analyst recommendations, institutional ownership and media sentiment.

Argent BioPharma has a beta of 1.05, suggesting that its stock price is 5% more volatile than the broader market. Comparatively, BSF Enterprise has a beta of 3.639, suggesting that its stock price is 264% more volatile than the broader market.

BSF Enterprise has higher revenue and earnings than Argent BioPharma. BSF Enterprise is trading at a lower price-to-earnings ratio than Argent BioPharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Argent BioPharmaN/AN/A-£17.53M-£0.24N/A
BSF Enterprise£51.07K42.51-£2.04M-£1.02N/A

1.1% of Argent BioPharma shares are owned by institutional investors. 17.8% of Argent BioPharma shares are owned by company insiders. Comparatively, 10.9% of BSF Enterprise shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Argent BioPharma's average media sentiment score of 0.00 equaled BSF Enterprise'saverage media sentiment score.

Company Overall Sentiment
Argent BioPharma Neutral
BSF Enterprise Neutral

Argent BioPharma has a net margin of -1,967.38% compared to BSF Enterprise's net margin of -2,505.69%. Argent BioPharma's return on equity of 279.26% beat BSF Enterprise's return on equity.

Company Net Margins Return on Equity Return on Assets
Argent BioPharma-1,967.38% 279.26% -108.57%
BSF Enterprise -2,505.69%-57.16%-20.65%

Summary

Argent BioPharma beats BSF Enterprise on 6 of the 10 factors compared between the two stocks.

How does BSF Enterprise compare to Celadon Pharmaceuticals?

BSF Enterprise (LON:BSFA) and Celadon Pharmaceuticals (LON:CEL) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability, media sentiment and risk.

10.7% of Celadon Pharmaceuticals shares are owned by institutional investors. 10.9% of BSF Enterprise shares are owned by company insiders. Comparatively, 65.1% of Celadon Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

BSF Enterprise has a beta of 3.639, suggesting that its stock price is 264% more volatile than the broader market. Comparatively, Celadon Pharmaceuticals has a beta of -0.26, suggesting that its stock price is 126% less volatile than the broader market.

BSF Enterprise has higher earnings, but lower revenue than Celadon Pharmaceuticals. Celadon Pharmaceuticals is trading at a lower price-to-earnings ratio than BSF Enterprise, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BSF Enterprise£51.07K42.51-£2.04M-£1.02N/A
Celadon Pharmaceuticals£123.38K66.61-£4.97M-£7.98N/A

In the previous week, BSF Enterprise's average media sentiment score of 0.00 equaled Celadon Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
BSF Enterprise Neutral
Celadon Pharmaceuticals Neutral

BSF Enterprise has a net margin of -2,505.69% compared to Celadon Pharmaceuticals' net margin of -9,520.00%. BSF Enterprise's return on equity of -57.16% beat Celadon Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
BSF Enterprise-2,505.69% -57.16% -20.65%
Celadon Pharmaceuticals -9,520.00%-131.82%-34.40%

Summary

BSF Enterprise beats Celadon Pharmaceuticals on 7 of the 11 factors compared between the two stocks.

How does BSF Enterprise compare to InnovaDerma?

BSF Enterprise (LON:BSFA) and InnovaDerma (LON:IDP) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, risk, profitability, institutional ownership, media sentiment, valuation, earnings and analyst recommendations.

In the previous week, BSF Enterprise's average media sentiment score of 0.00 equaled InnovaDerma'saverage media sentiment score.

Company Overall Sentiment
BSF Enterprise Neutral
InnovaDerma Neutral

InnovaDerma has a net margin of 0.00% compared to BSF Enterprise's net margin of -2,505.69%. InnovaDerma's return on equity of 0.00% beat BSF Enterprise's return on equity.

Company Net Margins Return on Equity Return on Assets
BSF Enterprise-2,505.69% -57.16% -20.65%
InnovaDerma N/A N/A N/A

InnovaDerma has higher revenue and earnings than BSF Enterprise. BSF Enterprise is trading at a lower price-to-earnings ratio than InnovaDerma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BSF Enterprise£51.07K42.51-£2.04M-£1.02N/A
InnovaDerma£9.82M0.00N/A-£7.50N/A

Summary

InnovaDerma beats BSF Enterprise on 4 of the 6 factors compared between the two stocks.

How does BSF Enterprise compare to HaloSource?

BSF Enterprise (LON:BSFA) and HaloSource (LON:HALO) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, institutional ownership, earnings, analyst recommendations, valuation and risk.

In the previous week, BSF Enterprise's average media sentiment score of 0.00 equaled HaloSource'saverage media sentiment score.

Company Overall Sentiment
BSF Enterprise Neutral
HaloSource Neutral

HaloSource has a net margin of 0.00% compared to BSF Enterprise's net margin of -2,505.69%. HaloSource's return on equity of 0.00% beat BSF Enterprise's return on equity.

Company Net Margins Return on Equity Return on Assets
BSF Enterprise-2,505.69% -57.16% -20.65%
HaloSource N/A N/A N/A

HaloSource has lower revenue, but higher earnings than BSF Enterprise. HaloSource is trading at a lower price-to-earnings ratio than BSF Enterprise, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BSF Enterprise£51.07K42.51-£2.04M-£1.02N/A
HaloSourceN/AN/AN/A-£3.72N/A

Summary

BSF Enterprise and HaloSource tied by winning 3 of the 6 factors compared between the two stocks.

How does BSF Enterprise compare to OptiBiotix Health?

BSF Enterprise (LON:BSFA) and OptiBiotix Health (LON:OPTI) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, dividends, profitability, risk, analyst recommendations, valuation, earnings and institutional ownership.

In the previous week, BSF Enterprise's average media sentiment score of 0.00 equaled OptiBiotix Health'saverage media sentiment score.

Company Overall Sentiment
BSF Enterprise Neutral
OptiBiotix Health Neutral

0.4% of OptiBiotix Health shares are held by institutional investors. 10.9% of BSF Enterprise shares are held by company insiders. Comparatively, 26.8% of OptiBiotix Health shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

BSF Enterprise has higher earnings, but lower revenue than OptiBiotix Health. OptiBiotix Health is trading at a lower price-to-earnings ratio than BSF Enterprise, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BSF Enterprise£51.07K42.51-£2.04M-£1.02N/A
OptiBiotix Health£1.29M3.65-£3.09M-£4.21N/A

OptiBiotix Health has a net margin of -332.69% compared to BSF Enterprise's net margin of -2,505.69%. BSF Enterprise's return on equity of -57.16% beat OptiBiotix Health's return on equity.

Company Net Margins Return on Equity Return on Assets
BSF Enterprise-2,505.69% -57.16% -20.65%
OptiBiotix Health -332.69%-77.85%-13.93%

BSF Enterprise has a beta of 3.639, meaning that its share price is 264% more volatile than the broader market. Comparatively, OptiBiotix Health has a beta of 1.82, meaning that its share price is 82% more volatile than the broader market.

Summary

BSF Enterprise beats OptiBiotix Health on 6 of the 11 factors compared between the two stocks.

Get BSF Enterprise News Delivered to You Automatically

Sign up to receive the latest news and ratings for BSFA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BSFA vs. The Competition

MetricBSF EnterprisePharmaceuticals IndustryHealthcare SectorLON Exchange
Market Cap£1.84M£13.76B£7.83B£2.84B
Dividend YieldN/A2.58%2.47%5.11%
P/E Ratio-0.8829.0834.3223.37
Price / Sales35.937.748.005.05
Price / Cash10.3015.7421.0220.23
Price / Book0.295.194.762.51
Net Income-£2.04M£2.88B£3.52B£5.88B
7 Day Performance-7.12%-3.90%-5.35%-0.01%
1 Month Performance-10.89%-3.99%-3.62%-2.15%
1 Year Performance-65.45%-7.16%-0.62%7.21%

BSF Enterprise Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BSFA
BSF Enterprise
N/AGBX 0.90
-15.5%
N/A-59.1%£1.84M£51.07KN/A12
RGT
Argent BioPharma
N/AN/AN/AN/A£8.31MN/AN/AN/A
CEL
Celadon Pharmaceuticals
N/AGBX 13.40
flat
N/AN/A£8.22M£123.38KN/A2,780
IDP
InnovaDerma
N/AN/AN/AN/A£8.14M£9.82MN/A8,720
HALO
HaloSource
N/AGBX 6.50
-3.7%
N/AN/A£7.61MN/AN/A390

Related Companies and Tools


This page (LON:BSFA) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners